These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26177273)

  • 1. Highlights of the 83rd European Atherosclerosis Society (EAS) annual Congress, Glasgow 22-25 March, 2015.
    Stock J
    Atherosclerosis; 2015 Sep; 242(1):45-7. PubMed ID: 26177273
    [No Abstract]   [Full Text] [Related]  

  • 2. New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines.
    Shrank WH; Barlow JF; Brennan TA
    JAMA; 2015 Oct; 314(14):1443-4. PubMed ID: 26258765
    [No Abstract]   [Full Text] [Related]  

  • 3. Antihyperlipidemic therapies targeting PCSK9: Novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Liu MH
    Int J Cardiol; 2015 Sep; 195():212-4. PubMed ID: 26048378
    [No Abstract]   [Full Text] [Related]  

  • 4. Improving the care of high-risk patients: the potential of PCSK9.
    Stock J
    Atherosclerosis; 2014 Feb; 232(2):420-2. PubMed ID: 24468158
    [No Abstract]   [Full Text] [Related]  

  • 5. Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention.
    Robinson JG; Heistad DD; Fox KA
    Atherosclerosis; 2015 Dec; 243(2):593-7. PubMed ID: 26545013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
    Lose JM; Dorsch MP; Bleske BE
    Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P; Just IA; Kaschina E
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in atherosclerosis: clinical potential of PCSK9 inhibition.
    Giunzioni I; Tavori H
    Vasc Health Risk Manag; 2015; 11():493-501. PubMed ID: 26345307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
    Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential peptides in atherosclerosis therapy.
    Marleau S; Mellal K; Huynh DN; Ong H
    Front Horm Res; 2014; 43():93-106. PubMed ID: 24943301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of and treatment options for increased lipoprotein(a)].
    Zsíros N; Paragh G; Harangi M
    Orv Hetil; 2014 Apr; 155(16):607-14. PubMed ID: 24733102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Latest developments in the treatment of lipoprotein (a).
    Bos S; Yayha R; van Lennep JE
    Curr Opin Lipidol; 2014 Dec; 25(6):452-60. PubMed ID: 25318824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9: is it fluoride for cardiology?
    King SB
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1331-2. PubMed ID: 25459045
    [No Abstract]   [Full Text] [Related]  

  • 17. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihyperlipidemic therapies targeting PCSK9.
    Weinreich M; Frishman WH
    Cardiol Rev; 2014; 22(3):140-6. PubMed ID: 24407047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PCSK9 inhibitors and dyslipidemias: an update on clinical evidence].
    Norata GD
    G Ital Cardiol (Rome); 2014 May; 15(5):301-5. PubMed ID: 25002170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.
    Milionis H; Liamis G; Elisaf M
    Expert Opin Biol Ther; 2015 Feb; 15(2):287-98. PubMed ID: 25491324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.